By exposing the mu-receptor (MOP-R) to more than one exogenous ligand, the administration during general anaesthesia of more than one opioid with principal action on the receptor may confound and lead to complications or unexpected outcomes. The giving of such a 'mixed message' can result in respiratory depression, excess sedation and delayed recovery to an unusual degree. We present a case of apparent extreme opioid sensitivity and discuss a possible mechanism. Such occurrences may be more common than previously realised.
CASE HISTORY
The female patient, aged 78 years with a body mass index of 31 and co-morbidities of hypertension and hiatus hernia, was known to have gallstones for the preceding two years and was admitted with acute cholecystitis. Regular medication included atenolol and simvastatin. On admission her serum sodium of 131 mmol/l, potassium 3.8 mmol/l, urea 7.1 mmol/l, creatinine 87 μmol/l, C-reactive protein 69.5 mg/ l, total bilirubin 18 μmol/l, alkaline phosphatase 170 IU/l, amylase 41 IU/l and white blood cell count of 17.9X10 9 /l were consistent with the diagnosis. Seven hours prior to the scheduled laparoscopic cholecystectomy the patient required analgesia and received tramadol 100 mg intravenously.
Anaesthesia was uneventfully induced with propofol 150 mg preceded by midazolam 2 mg and fentanyl 100 μg. Intubation was facilitated using rocuronium 50 mg and the patient was ventilated with a mixture of oxygen, air and sevoflurane using a circle system. Morphine 10 mg in total was given intraoperatively together with cyclizine 50 mg. The surgery lasted one hour and 45 minutes during which time she was ventilated to normocapnia and received Hartmann's solution 1500 ml and succinylated gelatin 500 ml (Gelofusine, BBraun AG, Melsungen. Germany).
Despite the reversal of residual muscle relaxation, confirmed by a nerve stimulator, the elimination of sevoflurane and a core temperature of 36.7°C, the patient did not regain consciousness. The presence of pinpoint pupils resulted in her receiving the opioid antagonist naloxone by titration, in aliquots of increasing size. She received 2000 μg in total over 90 minutes before she was sufficiently responsive to consider extubation. To exclude an idiosyncratic response to low dose midazolam, the benzodiazepine antagonist flumazenil 500 μg was administered by titration, but to no effect.
An additional 1600 μg of naloxone was required in the recovery area over a period of ninety minutes. Despite this large dose of antagonist the patient reported no postoperative pain for twenty-two hours following surgery, at which time a single intravenous dose of tramadol 50 mg provided adequate pain relief.
DISCUSSION
The extreme nature of this event and similar experiences, both personal and described by colleagues, prompted a close examination of this situation.
Opioid receptors belong to the class A family of seven transmembrane-spanning G proteincoupled receptors, activated by both endogenous and exogenous ligands.
Regulated by multiple mechanisms, all have only one binding cavity for agonists and antagonists. In addition to the four receptors that have been cloned, mu (MOP-R), delta (DOP-R), kappa (KOP-R), and nociceptin (NOP-R), there is evidence that additional opioid receptor phenotypes exist through posttranslational modifications, alternative mRNA splicing or tissue distribution of more than one receptor gene 1 .
All these complex receptors have an extracellular N-terminus and an intracellular C-terminus with the seven transmembrane-spanning domains making up the opioid binding pocket with distinct agonist and antagonist conformations. The binding cavities consist of an inner 'conserved region', composed of 18 residues that are identical between receptor subtypes, and a 'variable region' of 19 residues that are different. The latter are responsible for the subtype specificity of the various ligands 2 . The N-terminal tyrosine residue, described as the 'common message' within the structure of the ligand, is involved in its recognition at the base of the binding cavity, a mechanism common to all receptors. Access to the cavity may be inhibited by the receptor's extracellular loops limiting orientation in approach of the ligand and requiring favourable interactions within 3 .
Alkaloid agonist ligands, such as morphine, range in their ability to fill the upper section of the cavity while alkaloid antagonists such as naloxone act more deeply within it to sterically hinder activation of the receptor. The extracellular loops can also act as gate, allowing only certain ligands to pass. Most ligands are not completely rigid and show several possible conformations of the flexible elements, such as the N-cyclopropylmethyl group of morphine or the N-phenethyl group of fentanyl. The smaller alkaloids, such as morphine and naloxone, interact with the receptor in different spatial positions to those of the fentanyl analogues, which show high affinity binding with the phenyl ring orientated to the extracellular surface 2 . In mice and in humans variants can exist (including truncated receptors) which modulate the activity of other receptors. While retaining high affinity and selectivity for mu opioids, they differ structurally at the C-terminus, an important site for activation.
Maximal stimulation can vary among drugs and among variants, with an individual opioid acting as a pure agonist at one variant yet only as a partial agonist at another. The overall pharmacological activity of any mu opioid through distinct receptor mechanisms will therefore be the summation of the activation of all MOP-R including variants. Finely tuned opioid-related responses may rely upon a highly controlled expression of receptor variants, with the gene responsible undergoing extensive alternative splicing to account for the diversity 4 .
Clinicians have long observed differences in patient response to the same opioid, leading to a different analgesic and side-effect profile between patients. The complexity of the MOP-R, the existence of sub-types and the role of peripheral receptors in respiratory depression, for example, can explain significant differences observed among mu-agonists 5, 6 . The affinity, efficacy, dose and pharmacokinetic properties of the drug used will also influence the ultimate effect seen in the organism, as will the presence of other ligands in the system. When drugs are used in combination, the net effect will depend upon the intrinsic characteristics (efficacy and affinity) of the two drugs relative to each other and their relative concentrations at the site of action 7 .
The agonist morphine interacts differently with the MOP-R than do agonists such as fentanyl analogues, causing distinct adaptive responses affecting desensitization and tolerance 8 . Also, the unique and different binding mode proposed for the fentanyl analogues may, in part, explain the difficulties encountered in defining models of recognition at the MOP-R with immunologically distinct binding 9 .
Experience with buprenorphine has shown that the limited reversal effect of the antagonist naloxone does not appear to be related to naloxone's relatively short duration of action, but rather can be accounted for by the strong affinity of buprenorphine for the MOP-R binding sites and the relative inability of naloxone to displace it from these sites 10 . The binding of naloxone requires deep receptor penetration and this could be complicated by any mutation.
When there is delayed recovery from anaesthesia the diagnosis of central anticholinergic syndrome (CAS) should be considered if other causes have been excluded. Symptoms similar to CAS may be seen after high-dose fentanyl anaesthesia through binding to muscarinic receptors, but we used only a low dose of fentanyl. In our patient the presenting features included respiratory depression and pinpoint pupils rather than just excessive sedation, and we would not ascribe these to an effect of cyclizine.
Mixed opioid use during anaesthesia is common practice and often involves the administration of fentanyl at induction followed by an opioid of longer duration such as morphine, which is then continued postoperatively. This practice, however, exposes the MOP-R to more than one exogenous ligand, giving a mixed message that can lead to problems including unexpected respiratory depression, excess sedation and delayed recovery, in this case of more than three hours duration.
Through an effect at the receptor a situation somewhat analogous to that following buprenorphine is created. In addition, the situation is further confounded by the variable effects consequent to peripheral actions, (point) mutation and other receptor modifications. We believe that, for all patients, this may be a potential problem that is unpredictable and that may pass unrecognized. It merits further study. Unless a good clinical reason exists, we consider it is appropriate to administer only a single opioid during each general anaesthetic and that mixing of opioids should be avoided.
